Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

upload.jpg

See the World Pharma Today article here

Interview: N4 Pharma’s CEO Nigel Theobald discusses strategic moves and future of pharma

In an interview with World Pharma Today, Nigel Theobald, CEO N4 Pharma, answers questions about the company’s latest news and future plans. 

Key highlights from the discussion include:

Acquisition: our recent acquisition of Nanogenics Limited and how it enhances our product offerings in gene therapy.

Collaborative partnerships: our partnerships with institutions like the University of Queensland which drive forward our research and development efforts.

Regulatory pathways: how we plan to navigate regulatory approval processes with bodies like the Food and Drug Administration (FDA).

Commercialization strategies: how we plan to commercialize our products independently and through strategic partnerships.

Scalability and manufacturing: the scalability and manufacturing processes involved in producing Nuvec ® and LipTide ® , ensuring efficient production for commercial distribution.

Market impact: the potential market impact of ECP105 using LipTide® for glaucoma treatment, including projections for patient adoption and market penetration.

Long-term goals: our long-term aspirations in oncology, gene therapy, and vaccines, as we strive for Nuvec ® to be the go-to alternative to lipid nanoparticles for effective delivery of nucleic acids.

Read the interview published in World Pharma Today via the link below.

Please submit any questions you have below.

N4 Pharma’s CEO Nigel Theobald Discusses Strategic Moves and Future Outlook in Pharma